AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ALTERITY THERAPEUTICS LTD

0.380

-0.020-5.00%

Volume:560.61K

Turnover:217.27K

Market Cap:82.65M

PE:-3.42

High:0.410

Open:0.400

Low:0.370

Close:0.400

52wk High:0.785

52wk Low:0.350

Shares:217.51M

Float Shares:149.50M

Volume Ratio:1.42

T/O Rate:0.37%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.111

EPS(LYR):-0.111

ROE:-54.98%

ROA:-34.08%

PB:1.93

PE(LYR):-3.42

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Alterity Says Ath434 50 Mg Slows Functional Decline About 52% vs Placebo in Phase 2 Multiple System Atrophy Analysis

Alterity Therapeutics Limited: Ath434 50Mg Slowed MSA Functional Decline by About 52% vs Placebo at Week 52 - SEC Filing

THOMSON REUTERS

Alterity Therapeutics Announces Annual Shareholder Meeting

Alterity Therapeutics Director Peter Ashley Marks Acquires 47,620 Shares for $0.50 Each, Valued at $23,810

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/ATH.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ATH.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ATH.AU\",,,,,undefined,":{"symbol":"ATH.AU","market":"AU","secType":"STK","nameCN":"ALTERITY THERAPEUTICS LTD","latestPrice":0.38,"timestamp":1791349920000,"preClose":0.4,"halted":0,"volume":560606,"delay":0,"changeRate":-0.050000000000000044,"nameEN":"ALTERITY THERAPEUTICS LTD","floatShares":149498066,"shares":217508326,"eps":-0.1112,"marketStatus":"Not Yet Opened","change":-0.02,"latestTime":"10-07 16:12:00 AEDT","open":0.4,"high":0.41,"low":0.37,"amount":217271,"amplitude":0.1,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.1112,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1791414000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.4,"openAndCloseTimeList":[[1791327600000,1791349200000]],"volumeRatio":1.4214904954719174,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"ATH.AU","preClose":0.4,"auctionPrice":0.38,"auctionVolume":1474,"auction":3,"marketStatus":"盘后竞价","timestamp":1791349791240}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ATH.AU\",,,,,undefined,":{"symbol":"ATH.AU","floatShares":149498066,"roa":"-34.08%","roe":"-54.98%","lyrEps":-0.1112,"volumeRatio":1.4214904954719174,"shares":217508326,"dividePrice":0,"high":0.41,"amplitude":0.1,"preClose":0.4,"low":0.37,"week52Low":0.35,"pbRate":"1.93","psRate":"22.90","week52High":0.785,"institutionHeld":0,"latestPrice":0.38,"eps":-0.1112,"divideRate":0,"volume":560606,"delay":0,"ttmEps":-0.1112,"open":0.4,"prevYearClose":0.4,"prevWeekClose":0.38,"prevMonthClose":0.402,"prevQuarterClose":0.402,"fiveDayClose":0.402,"twentyDayClose":0.505,"sixtyDayClose":0.575},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATH.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2026-06-03","symbol":"ATH.AU","defaultRemindTime":1780444800000,"type":"split","dateTimestamp":1780408800000,"forFactor":50,"toFactor":1,"ratio":50}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATH.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATH.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673092697","title":"Alterity Says Ath434 50 Mg Slows Functional Decline About 52% vs Placebo in Phase 2 Multiple System Atrophy Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2673092697","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673092697?lang=en_us&edition=fundamental","pubTime":"2026-10-05 18:16","pubTimestamp":1791195409,"startTime":"0","endTime":"0","summary":"Alterity says ATH434 50 mg slows functional decline about 52% vs placebo in Phase 2 multiple system atrophy analysisAlterity Therapeutics presented new Phase 2 analyses of ATH434 in multiple system at","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDL3c6gkq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ATH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673709155","title":"Alterity Therapeutics Limited: Ath434 50Mg Slowed MSA Functional Decline by About 52% vs Placebo at Week 52 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2673709155","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673709155?lang=en_us&edition=fundamental","pubTime":"2026-10-05 18:08","pubTimestamp":1791194907,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nFWN45Q01J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATH.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670441260","title":"Alterity Therapeutics Announces Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2670441260","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670441260?lang=en_us&edition=fundamental","pubTime":"2026-09-25 18:03","pubTimestamp":1790330612,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics announces annual shareholder meetingAlterity Therapeutics will hold its annual general meeting on Nov. 20, 2026.Director election nominations close Oct. 2, 2026.Disclaimer:This n","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260925:nNDL8dnCLc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ATH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666130814","title":"Alterity Therapeutics Director Peter Ashley Marks Acquires 47,620 Shares for $0.50 Each, Valued at $23,810","url":"https://stock-news.laohu8.com/highlight/detail?id=2666130814","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666130814?lang=en_us&edition=fundamental","pubTime":"2026-09-09 07:02","pubTimestamp":1788908538,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics director Peter Ashley Marks acquires 47,620 shares for $0.50 each, valued at $23,810Alterity Therapeutics director Peter Ashley Marks increased indirect ownership via Lampam Pty ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL7NngY5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Alterity Therapeutics Director Peter Ashley Marks Acquires 47,620 Shares for $0.50 Each, Valued at $23,810","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ATH.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":14,"pageCount":1,"totalSize":54,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ATH.AU\",params:#limit:6,delay:true,,,undefined,":[]}}